Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Moderate to Severe Hidradenitis Suppurativa
NCT04430855Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of upadacitinib in hidradenitis suppurativa (HS), sponsored by AbbVie Inc.. Started Jul 2020; status: completed.
02
Drugs
upadacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04430855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430855.